Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 26

1.

Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs.

Marquard AM, Eklund AC, Joshi T, Krzystanek M, Favero F, Wang ZC, Richardson AL, Silver DP, Szallasi Z, Birkbak NJ.

Biomark Res. 2015 May 1;3:9. doi: 10.1186/s40364-015-0033-4. eCollection 2015.

2.

Tracking the Genomic Evolution of Esophageal Adenocarcinoma through Neoadjuvant Chemotherapy.

Murugaesu N, Wilson GA, Birkbak NJ, Watkins TB, McGranahan N, Kumar S, Abbassi-Ghadi N, Salm M, Mitter R, Horswell S, Rowan A, Phillimore B, Biggs J, Begum S, Matthews N, Hochhauser D, Hanna GB, Swanton C.

Cancer Discov. 2015 May 23. [Epub ahead of print]

PMID:
26003801
3.

Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial.

Jamal-Hanjani M, A'Hern R, Birkbak NJ, Gorman P, Grönroos E, Ngang S, Nicola P, Rahman L, Thanopoulou E, Kelly G, Ellis P, Barrett-Lee P, Johnston SR, Bliss J, Roylance R, Swanton C.

Ann Oncol. 2015 Jul;26(7):1340-6. doi: 10.1093/annonc/mdv178. Epub 2015 May 23.

PMID:
26003169
4.

Clonal status of actionable driver events and the timing of mutational processes in cancer evolution.

McGranahan N, Favero F, de Bruin EC, Birkbak NJ, Szallasi Z, Swanton C.

Sci Transl Med. 2015 Apr 15;7(283):283ra54. doi: 10.1126/scitranslmed.aaa1408.

PMID:
25877892
5.

Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome.

Favero F, McGranahan N, Salm M, Birkbak NJ, Sanborn JZ, Benz SC, Becq J, Peden JF, Kingsbury Z, Grocok RJ, Humphray S, Bentley D, Spencer-Dene B, Gutteridge A, Brada M, Roger S, Dietrich PY, Forshew T, Gerlinger M, Rowan A, Stamp G, Eklund AC, Szallasi Z, Swanton C.

Ann Oncol. 2015 May;26(5):880-7. doi: 10.1093/annonc/mdv127. Epub 2015 Mar 2.

6.

SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair.

Kanu N, Grönroos E, Martinez P, Burrell RA, Yi Goh X, Bartkova J, Maya-Mendoza A, Mistrík M, Rowan AJ, Patel H, Rabinowitz A, East P, Wilson G, Santos CR, McGranahan N, Gulati S, Gerlinger M, Birkbak NJ, Joshi T, Alexandrov LB, Stratton MR, Powles T, Matthews N, Bates PA, Stewart A, Szallasi Z, Larkin J, Bartek J, Swanton C.

Oncogene. 2015 Mar 2. doi: 10.1038/onc.2015.24. [Epub ahead of print]

PMID:
25728682
7.

Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data.

Favero F, Joshi T, Marquard AM, Birkbak NJ, Krzystanek M, Li Q, Szallasi Z, Eklund AC.

Ann Oncol. 2015 Jan;26(1):64-70. doi: 10.1093/annonc/mdu479. Epub 2014 Oct 15.

8.

Expression of regulators of mitotic fidelity are associated with intercellular heterogeneity and chromosomal instability in primary breast cancer.

Roylance R, Endesfelder D, Jamal-Hanjani M, Burrell RA, Gorman P, Sander J, Murphy N, Birkbak NJ, Hanby AM, Speirs V, Johnston SR, Kschischo M, Swanton C.

Breast Cancer Res Treat. 2014 Nov;148(1):221-9. doi: 10.1007/s10549-014-3153-x. Epub 2014 Oct 7.

PMID:
25288231
9.

Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers.

Gulati S, Martinez P, Joshi T, Birkbak NJ, Santos CR, Rowan AJ, Pickering L, Gore M, Larkin J, Szallasi Z, Bates PA, Swanton C, Gerlinger M.

Eur Urol. 2014 Nov;66(5):936-48. doi: 10.1016/j.eururo.2014.06.053. Epub 2014 Jul 19.

10.

Enhancing reproducibility in cancer drug screening: how do we move forward?

Hatzis C, Bedard PL, Birkbak NJ, Beck AH, Aerts HJ, Stem DF, Shi L, Clarke R, Quackenbush J, Haibe-Kains B.

Cancer Res. 2014 Aug 1;74(15):4016-23. doi: 10.1158/0008-5472.CAN-14-0725. Epub 2014 Jul 11. Review. Erratum in: Cancer Res. 2014 Sep 15;74(18):5348. Stern, David F [corrected to Stem, David F].

PMID:
25015668
11.

Tracking genomic cancer evolution for precision medicine: the lung TRACERx study.

Jamal-Hanjani M, Hackshaw A, Ngai Y, Shaw J, Dive C, Quezada S, Middleton G, de Bruin E, Le Quesne J, Shafi S, Falzon M, Horswell S, Blackhall F, Khan I, Janes S, Nicolson M, Lawrence D, Forster M, Fennell D, Lee SM, Lester J, Kerr K, Muller S, Iles N, Smith S, Murugaesu N, Mitter R, Salm M, Stuart A, Matthews N, Adams H, Ahmad T, Attanoos R, Bennett J, Birkbak NJ, Booton R, Brady G, Buchan K, Capitano A, Chetty M, Cobbold M, Crosbie P, Davies H, Denison A, Djearman M, Goldman J, Haswell T, Joseph L, Kornaszewska M, Krebs M, Langman G, MacKenzie M, Millar J, Morgan B, Naidu B, Nonaka D, Peggs K, Pritchard C, Remmen H, Rowan A, Shah R, Smith E, Summers Y, Taylor M, Veeriah S, Waller D, Wilcox B, Wilcox M, Woolhouse I, McGranahan N, Swanton C.

PLoS Biol. 2014 Jul 8;12(7):e1001906. doi: 10.1371/journal.pbio.1001906. eCollection 2014 Jul.

12.

STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypes.

Xiang M, Birkbak NJ, Vafaizadeh V, Walker SR, Yeh JE, Liu S, Kroll Y, Boldin M, Taganov K, Groner B, Richardson AL, Frank DA.

Sci Signal. 2014 Jan 28;7(310):ra11. doi: 10.1126/scisignal.2004497.

13.

Computational optimisation of targeted DNA sequencing for cancer detection.

Martinez P, McGranahan N, Birkbak NJ, Gerlinger M, Swanton C.

Sci Rep. 2013 Dec 3;3:3309. doi: 10.1038/srep03309.

14.

Inconsistency in large pharmacogenomic studies.

Haibe-Kains B, El-Hachem N, Birkbak NJ, Jin AC, Beck AH, Aerts HJ, Quackenbush J.

Nature. 2013 Dec 19;504(7480):389-93. doi: 10.1038/nature12831. Epub 2013 Nov 27.

15.

Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.

Birkbak NJ, Kochupurakkal B, Izarzugaza JM, Eklund AC, Li Y, Liu J, Szallasi Z, Matulonis UA, Richardson AL, Iglehart JD, Wang ZC.

PLoS One. 2013 Nov 12;8(11):e80023. doi: 10.1371/journal.pone.0080023. eCollection 2013.

16.

HELQ promotes RAD51 paralogue-dependent repair to avert germ cell loss and tumorigenesis.

Adelman CA, Lolo RL, Birkbak NJ, Murina O, Matsuzaki K, Horejsi Z, Parmar K, Borel V, Skehel JM, Stamp G, D'Andrea A, Sartori AA, Swanton C, Boulton SJ.

Nature. 2013 Oct 17;502(7471):381-4. doi: 10.1038/nature12565. Epub 2013 Sep 4.

17.

Parallel evolution of tumour subclones mimics diversity between tumours.

Martinez P, Birkbak NJ, Gerlinger M, McGranahan N, Burrell RA, Rowan AJ, Joshi T, Fisher R, Larkin J, Szallasi Z, Swanton C.

J Pathol. 2013 Aug;230(4):356-64. doi: 10.1002/path.4214.

PMID:
23716380
18.

Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome.

Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, Liu J, Etemadmoghadam D, Miron A, Salvesen HB, Mitchell G, DeFazio A, Quackenbush J, Berkowitz RS, Iglehart JD, Bowtell DD; Australian Ovarian Cancer Study Group, Matulonis UA.

Clin Cancer Res. 2012 Oct 15;18(20):5806-15. doi: 10.1158/1078-0432.CCR-12-0857. Epub 2012 Aug 21.

19.

Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.

Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, Tung N, Ryan PD, Garber JE, Silver DP, Szallasi Z, Richardson AL.

Cancer Discov. 2012 Apr;2(4):366-75. doi: 10.1158/2159-8290.CD-11-0206. Epub 2012 Mar 22. Erratum in: Cancer Discov. 2013 Aug;3(8):952.

20.

Jetset: selecting the optimal microarray probe set to represent a gene.

Li Q, Birkbak NJ, Gyorffy B, Szallasi Z, Eklund AC.

BMC Bioinformatics. 2011 Dec 15;12:474. doi: 10.1186/1471-2105-12-474.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk